A nationally-published, award-winning journalist, Alex Biese joined the CURE team as an assistant managing editor in April 2023. Prior to that, Alex's work was published in outlets including the Chicago Sun-Times, MTV.com, USA TODAY and the Press of Atlantic City. Alex is a member of NLGJA: The Association of LGBTQ+ Journalists, and also performs at the Jersey Shore with the acoustic jam band Somewhat Relative.
FDA Biologics License Application Filed for Obe-Cel for Adult R/R B-ALL
November 29th 2023Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).
Read More
Lung Cancer Survivor Tells Patients ‘Stay Positive, Put Yourself in Good Hands’
November 26th 2023Diane Messick, a three-time lung cancer survivor, tells CURE® about her cancer journey which has included a segmentectomy, a lobectomy and radiation treatment since receiving her first diagnosis in 2017.
Read More
Education Crucial in Cancer, ‘One of The Most Confusing Areas of Medical Treatment’
November 24th 2023As part of its Speaking Out® video series, CURE® spoke Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, about education disparities among patients with lung cancer.
Read More
Treatment Advancements Happening in Lung Cancer As Unmet Needs Remain
November 24th 2023As part of its Speaking Out® video series, CURE® spoke Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, about advancements in treating non-small cell lung cancer and the unmet needs that persist for patients.
Read More
Pelabresib Plus Jakafi Reduces Spleen Volume, Myelofibrosis Symptoms
November 22nd 2023Findings of MANIFEST-2 show “valuable evidence that the addition of pelabresib offers meaningful improvements over JAK inhibitor monotherapy as a first-line approach for patients with myelofibrosis,” according to one expert.
Read More
FDA Approves Truqap Plus Hormone Thearpy for Some With HR-Positive, HER-Negative Breast Cancer
November 16th 2023Truqap (capivasertib) with fulvestrant has been approved for the treatment of adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, the FDA announced.
Read More
Supplements May Lead to Financial, Adherence Issues in Breast Cancer
November 11th 2023Up to a quarter of patients with breast cancer face financial burden due to the cost of supplements, complimentary therapy and alternative medicines which “may decrease adherence to prescribed medications,” researchers found.
Read More
FDA Approves Fruzaqla for Previously Treated Metastatic Colorectal Cancer
November 9th 2023Patients with metastatic colorectal cancer are eligible for treatment with Fruzaqla, an oral targeted therapy, following treatment via fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy as well as an anti-VEGF therapy, and, if their disease RAS wild-type and medically appropriate, an anti-EGFR therapy.
Read More
CLL and Its Treatment Can Heighten Patients’ Risk of Infections
November 8th 2023Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated Patient® CLL Summit.
Read More
Survival May Not Differ by Race in Multiple Myeloma Treated With Abecma
November 6th 2023Researchers have found that, among patients with relapsed/refractory multiple myeloma who received treatment with the CAR-T cell therapy Abecma, race and ethnicity played roles in safety and response but not survival.
Read More